The SP@M treatment led to a significant decrease in the fluorescence intensity of CD86 (the phenotypic marker of M1-like macrophages) and an increase in the intensity of CD206 (the phenotypic marker of M2-like macrophages), indicating the remission of pro-inflammatory microenvironment (Supplementary Fig
A patient with gut symptoms may need evaluation for inflammatory bowel disease, infection, celiac disease, medication effects, food reactions, or other causes
[Google Scholar] Hasanuzzaman M, Nahar K, Alam MM, Roychowdhury R, Fujita M
Graves' disease and mental disorders
Adalimumab Drug and Antidrug Antibody Levels do Not Predict Flare Risk After Stopping Adalimumab in RA Patients With Low Disease Activity
Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM, Bharucha AE, Rocca WA